LGALS3BP expression is correlated with tumor differentiation grade and recurrent disease during chemotherapy, suggesting the potential use of LGALS3BP and CA125 for ovarian cancer detection and monitoring [46]. This evidence concerns the gene LGALS3BP and neoplasm.